Manipulating the Mouse Genome to Engineer Precise Functional Syntenic Replacements with Human Sequence  by Wallace, Helen A.C. et al.
ResourceManipulating the Mouse Genome to
Engineer Precise Functional Syntenic
Replacements with Human Sequence
Helen A.C. Wallace,1 Fatima Marques-Kranc,2 Melville Richardson,1 Francisco Luna-Crespo,1
Jackie A. Sharpe,2 Jim Hughes,2 William G. Wood,2 Douglas R. Higgs,2 and Andrew J.H. Smith1,*
1 Institute for Stem Cell Research, University of Edinburgh, King’s Buildings, West Mains Road, Edinburgh EH9 3JQ,
United Kingdom
2MRC Molecular Haematology Unit, Weatherall Institute for Molecular Medicine, University of Oxford, John Radcliffe Hospital,
Oxford OX3 9DS, United Kingdom
*Correspondence: andrew.smith@ed.ac.uk
DOI 10.1016/j.cell.2006.11.044SUMMARY
We have devised a strategy (called recombi-
nase-mediated genomic replacement, RMGR)
to allow the replacement of large segments
(>100 kb) of the mouse genome with the equiv-
alent human syntenic region. The technique in-
volves modifying a mouse ES cell chromosome
and a human BAC by inserting heterotypic lox
sites to flank the proposed exchange interval
and then using Cre recombinase to achieve
segmental exchange. We have demonstrated
the feasibility of this approach by replacing
the mouse a globin regulatory domain with the
human syntenic region and generating homozy-
gous mice that produce only human a globin
chains. Furthermore, modified ES cells can be
used iteratively for functional studies, and
here, as an example, we have used RMGR to
produce an accurate mouse model of human
a thalassemia. RMGR has general applicability
andwill overcome limitations inherent in current
transgenic technology when studying the ex-
pression of human genes and modeling human
genetic diseases.
INTRODUCTION
Studies of how human genes are normally regulated and
the effects of mutations that cause human genetic disease
are limited by the availability of appropriate primary cells
and tissues and the necessary constraints on experimen-
tal interventions. Consequently, over the past 20 years,
transgenic mice have become important experimental
models to understand how human genes are regulated.
Small transgenes, however, often do not contain all of
the cis-acting elements required for fully regulated expres-
sion since such sequences may be found tens or evenhundreds of kilobases from the gene in question (Kleinjan
and van Heyningen, 2005). Even when large transgenes
derived from PACs, BACs or YACs are used, they are fre-
quently rearranged; it is often very difficult to fully analyze
their structural integrity and copy number (Peterson et al.,
1998). Furthermore, their expression is often influenced by
their position of integration in the genome (Alami et al.,
2000; Kaufman et al., 1999). Making and characterizing
directed mutations for structure/function studies is also
difficult when using such large molecules. Even when suc-
cessful, the interpretation of these transgenic experiments
is complicated by the fact that the endogenous mouse
genes are still present unless bred against mice in which
they have been deleted or inactivated by homologous
recombination.
A complementary approach is to identify the mouse
ortholog and alter this gene or its regulatory elements by
homologous recombination using conventional gene-
targeting methods (Nagy, 2003). Clearly, mutating a single
gene at its normal chromosomal locus avoids many of the
problems associated with transgenes (copy number dif-
ferences, complex mapping problems, position effects),
and, in this process, the normal endogenous gene does
not remain intact to complicate the analysis. However,
there is increasing evidence demonstrating considerable
differences in the ways in which orthologous human and
mouse genes are normally regulated. In many instances,
mutations known to cause disease in human do not mimic
the phenotype when introduced into the mouse ortholog
(Colledge et al., 1995; Engle et al., 1996; Garrick et al.,
2006). These include the a globin locus, where deletion
of the major regulatory element causes a much milder
condition in mouse than in human (Anguita et al., 2002).
Therefore, although mouse models have provided many
insights into human genetic disease, it is becoming in-
creasingly clear that they are also beset by inherent
problems and difficulties in interpretation resulting from
differences in basic biological processes that have
evolved over the 70 million years of evolution that separate
humans and mice.Cell 128, 197–209, January 12, 2007 ª2007 Elsevier Inc. 197
Clearly, the next step in developing mouse models of
human disease is to replace large segments (100–1000s
kb) of the mouse genome with the wild-type or mutated
syntenic region of the human sequence, thereby including
all remote regulatory elements and inserting the human
segment as a single copy at a natural chromosomal posi-
tion for the genes contained within it. A range of chromo-
some-engineering technologies are now available that,
combined in a novel way, could make this feasible (Yu
and Bradley, 2001; Copeland et al., 2001; Muyrers et al.,
2001; Testa et al., 2003; Valenzuela et al., 2003; Yang
and Seed, 2003), including application of various hetero-
typic site-specific recombination systems (Cre, FLP,
fC31) to achieve efficient exchange of sequence cas-
settes at targeted chromosomal loci, a process known
as recombinase-mediated cassette exchange (RMCE)
(Baer and Bode, 2001).
In this study, we have combined various aspects of
these technologies to develop what we believe to be
a new, general strategy for replacing large segments of
the mouse genome with wild-type or mutated syntenic
regions of the human genome. We refer to this process
as recombinase-mediated genomic replacement (RMGR).
This allows precise, reproducible, genetically selectable
genomic replacement on a scale not previously attained
and should be generally applicable to large-scale modifi-
cation of the mouse genome. We have established a ‘‘proof
of principle’’ for its application in generating ‘‘humanized’’
mice by replacing the syntenic region encompassing the
mouse a globin regulatory domain (the region containing
all cis-acting sequences required for fully regulated ex-
pression of the a globin genes) with human BAC-derived
sequence in ES cells and subsequently deriving viable
mice homozygous for this syntenic substitution producing
only human a-globin chains. In addition, we have demon-
strated the potential of this approach for making authentic
mouse models of human disease by replacing the mouse
region with a recombineered human BAC in which the
a globin major regulatory element has been deleted from
the a globin regulatory domain. This created a model of
a thalassemia that faithfully mimics the phenotype of
patients with this common human genetic disease.
RESULTS
Genomic Replacement Strategy for Substitution
of the a Globin Gene Domain
We set out to exchange an extensive part of the mouse
genome with its human equivalent in a region where the
consequences could be clearly analyzed. We chose the re-
gion encompassing theaglobin gene cluster since this has
been fully characterized both structurally (Flint et al., 2001;
Hughes et al., 2005; Kielman et al., 1996) and functionally
(Anguita et al., 2001, 2002, 2004) in both mouse and
man. The gene order and transcriptional orientation of
the globin genes and other widely expressed genes flank-
ing them in this segment of the genome are highly con-
served (Figure 1); a multispecies DNA comparison shows198 Cell 128, 197–209, January 12, 2007 ª2007 Elsevier Inc.that the region of most conserved synteny extends from
the DIST gene (a rhomboid-like gene also known as
c16orf8, gene 5 in Figure 1) to the q globin gene (Hughes
et al., 2005). This region contains all known multispecies
conserved regulatory elements (MCS-Rs), the corre-
sponding erythroid-specific DNase1 hypersensitive sites
and well-defined segments of chromatin that become
acetylated specifically in erythroid cells (Anguita et al.,
2001, 2002; Higgs et al., 1998). This region is therefore
thought to encompass the entire a globin regulatory region
(Figure 1).
In outline, the plan involved insertion of noninteracting
(heterospecific) lox recombination sites (loxP and lox511)
into positions (in the Dist and q genes, respectively) flank-
ing the a globin regulatory domain in the mouse ES cell
chromosome and in the corresponding regions of a BAC
(344L6) that spans the entire (120 kb) human a globin
region. In the presence of Cre recombinase, reciprocal
exchange of sequence between the BAC and mouse
chromosome should occur since only the compatible
loxP/loxP and lox511/lox511 sites will recombine (Bethke
and Sauer, 1997) and thus result in replacement of the
entire mouse regulatory region in the ES cell genome
with the corresponding human region (Figure 1).
We chose the fourth intron of theDIST gene to insert the
loxP sites (upstream exchange points) in both mouse (ES
cells) and human (BAC) sequences and the second intron
of the 30 q gene in mouse (ES cells) and the corresponding
region of the second intron of the single human q gene
(BAC) (Figures 1–3) to insert the lox511 sites (downstream
exchange points). When recombination is activated, this
should result in the exchange of 117 kb of human
sequence for the equivalent 85 kb of mouse sequence,
creating a hybrid human-mouse DIST gene upstream
and a hybrid human-mouse q gene downstream in the
recombinant mouse chromosome.
Targeted Modifications of the a Globin Regulatory
Domain in Mouse ES Cells
The strategy required the sequential insertion of a loxP site
and then a lox511 site (in inverted orientation) into the
upstream and downstream positions of the mouseaglobin
cluster by conventional homologous recombination
(Mansour et al., 1988). The vectors designed to achieve
this also integrated genetic markers directly linked to the
loxP and lox511 sites to enable selection of the chromo-
some replacement in the second stage. Positive genetic
selection for loxP 3 loxP recombination involved re-
construction of a functional hypoxanthinephosphoribosyl-
transferase (Hprt) minigene from defective 50 and 30
components (Smith et al., 1995), and negative selection
for lox511 3 lox511 recombination involved the use of
HSV thymidine kinase (tk) genes.
For the mouse Dist gene, a targeting vector containing
a frt/I-SceI/Hprt-D3
0
/loxP/MC1neo/loxP cassette (Fig-
ure 2A) was electroporated into HPRT-deficient (HPRT)
E14-TG2a.IV ES cells, and correctly targeted clones
were obtained (Figure 2B). One of these Dist-targeted
Figure 1. The Chromosomal Localization and Organization of the Human and Mouse a Globin Clusters
The human cluster (16p13.3) is located close to the telomere (oval), whereas the mouse cluster lies at an interstitial chromosomal position (11qA4). The
globin genes are shown as labeled red boxes. Other human genes and their mouse orthologs are annotated as previously described (Flint et al., 1997)
3, IL9RP3; 3.1, POLR3K; 4, c16orf33; 5,C16orf8 (Dist); 6,MPG; 7,C16orf35; and 16, LUC7L; and shown as colored boxes encoded by the top (above
the line, 50 to 30 left to right) or bottom (below the line, 50 to 30 right to left) DNA strand. Note that two genes (POLR3K and aD) are found only in the
human cluster. IL9RP3 is a pseudogene in man but a functional gene in mouse. A gray line above each cluster represents the domain of acetylation
that appears only in erythroid cells. MCS-R refer to multispecies conserved regulatory elements. Below this in each cluster are known erythroid-spe-
cific (red arrows) and constitutive (black arrows) DNaseI hypersensitive sites. Above this in each cluster is the extent of the a globin region exchanged
between man (BAC) and mouse (ES cells) delimited upstream by the loxP site (yellow triangles) and downstream by the lox511 site (purple triangles).
The orientation of the loxP and lox511 sites is indicated by the directionality of the triangles.clones was used for a second round of homologous re-
combination to target the q gene using a vector with the
PGKpuro/MC1tk/lox511/I-SceI cassette (Figure 2C), and
several independently targeted clones were obtained.
Double Dist-q targeted clones should contain the inte-
grated cassettes either on the same chromosome (in-cis
targeting) or on each of the two homologs (in-trans target-
ing). We distinguished these based on the efficiency of
Cre-mediated recombination when a plasmid pBS-loxP/
Hprt-D5
0
/lox511, coelectroporated with a Cre expression
plasmid, interacted with the integrated cassettes recon-
structing a functional Hprt minigene. Cells with sites in-
cis should result in a higher frequency of recombination
relative to those in-trans, as measured by the frequency
of HPRT+ colonies (see Supplemental Data Section S3,
Figure S1, and Table S1, available with this article online).
On this basis, three from 12 independent cell lines (2/
B-6, 2/H-1, and 2/H-10) were assigned as having in-
cis-targeted Dist and q genes.
Targeted Modifications of the Human a Globin
Cluster in a BAC
A human BAC clone, 344L6, covering the interval from 3
kb upstream of the IL-9RP3 pseudogene to 18 kb down-stream of the q gene provided the human sequences.
This BAC was modified by inserting loxP and lox511 sites
(in the equivalent positions and in the same orientations
as in the mouse chromosome) using l Red-mediated ho-
mologous recombination in the E. coli strain DY380 (Lee
et al., 2001). The human DIST gene was targeted with
the vector containing the I-SceI/loxP/PGK-Tn903hyg/
loxP/Hprt-D5
0
/frt cassette (Figure 3A), and the q gene was
targeted with the vector containing the lox511/PGK-
Tn903neo/MC1tk/I-SceI cassette (Figure 3B). Finally, it
was necessary to remove a second, pre-existing, endog-
enous lox511 site present in the BACe3.6 vector; an addi-
tional recombination event was therefore carried out to
replace the endogenous lox511 site with a blasticidin
selection cassette (Figure 3C), which consequently would
also permit the detection of any potential random BAC
backbone DNA integration in ES cells.
Selection and Characterization of the Genome
Replacement Event
The vectors used to target the mouse and human DIST
genes (Figures 2A and 3A) inserted the loxP sites and their
linkedHprt-D3
0
andHprt-D5
0
sequences, respectively, in the
opposite transcriptional orientation to the Dist gene. ThisCell 128, 197–209, January 12, 2007 ª2007 Elsevier Inc. 199
Figure 2. Targeting the Mouse Dist and 30 q Genes
(A) A cassette frt/I-SceI/Hprt-D3
0
/loxP/MC1neo/loxP was targeted to mouse Dist gene intron 4 using a linearized replacement vector with a diphtheria
toxin (DT-A) gene for negative selection (Yagi et al., 1990). (B) Southern blot analysis of the parental ES cell line (lanes 1, 3) and aDist-targeted cell line
(lanes 2, 4) digested withSpeI (0.65% gel). The normal 17.5 kb fragment is reduced to 16.2 kb when hybridized with theDist 50 probe (lanes 1, 2) and to
6.3 kb when hybridized with theDist 30 probe (lanes 3, 4). (C) A cassette PGKpuro/MC1tk/lox511/I-SceI was targeted to mouse 30 q gene intron 2 in the
Dist-targeted cell line using a linearized replacement vector as above. (D) Southern blot analysis of the parental ES cell line (lanes 1, 4), aDist-targeted
cell line (lanes 2, 5), and a Dist/q double-targeted cell line (lanes 3 and 6) digested with PstI (0.8% gel). The normal 9.6 kb fragment is reduced to a 6.6
kb fragment when hybridized with the 30 q gene 30 probe (lanes 1, 3) and to a 5.0 kb fragment when hybridized with the 30 q gene 50 probe (lanes 4, 6).
N.B. the 4.6 kb restriction fragment seen with the 50 probe corresponds to the upstream mouse 50 q gene sequences; all other restriction fragment
sizes are derived from the 30 q gene. Symbols: exons, clear rectangles (some numbered); noncoding sequences and introns, narrow clear rectangles;
selection markers, blue boxes; Hprt-D3
0
segment, red box (clear indent indicates promoter, blunt end indicates break in intron sequence); lox, frt, and
I-SceI sequences, see key, orientations indicated by directionality of triangles and chevrons; probes, black boxes; vector homology arms, dotted lines
with sizes in kilobases (kb); predicted homologous recombination between vector and chromosome, crossed black lines; restriction sites, thin vertical
lines; diagnostic restriction fragments, dashed lines with arrow heads, size in kilobases (kb). For clarity, the pBS component of the vectors and their
site for linearization are not shown. Some components are not drawn to scale.should create a reconstructed Hprt minigene after Cre-
mediated recombination located in the recombinant
mouse chromosome. The vectors used to target the
mouse and human q genes (Figures 2C and 3B) inserted
the lox511 sites in the same orientation but opposite to
that of the loxP site. The relative order of the lox511 and
linked HSV thymidine kinase negative selection marker,
MC1tk, should, after Cre-mediated recombination, result
in a recombinant mouse chromosome lacking a negative
selection marker.
This overall arrangement of targeted sequences in the
ES cells and the BAC necessary to implement the desired
Cre-mediated exchange is illustrated in Figures 4A and
4B. The reciprocal recombinant BAC product (not shown)200 Cell 128, 197–209, January 12, 2007 ª2007 Elsevier Inc.should remain unintegrated and therefore be lost after cell
division. ES cells with the resulting recombinant mouse
chromosome will have an HPRT+, ganciclovir-resistant
phenotype.
Two cell lines, 2/B-6 and 2/H-1, with putative in-cis-tar-
geted events at the Dist and q loci were coelectroporated
in an approximate 1:10 molar ratio with the modified BAC
and a Cre recombinase expressing plasmid (pCAGGS-
Cre-IRESpuro) (Smith et al., 2002), and HPRT+ cells
subsequently selected in medium with hypoxanthine,
aminopterin, and thymidine (HAT). HAT-resistant (HATR)
colonies were obtained at an approximate frequency of
1 3 108 (an average value determined from three inde-
pendent electroporations). Two independent colonies
Figure 3. Targeting into BAC 344L6
(A) Vector used to insert a I-SceI/loxP/PGK-Tn905hyg/loxP/Hprt-D5
0
/frt cassette into human DIST gene intron 4. (B) Vector used to insert a lox511/
PGK-Tn905neo/MC1tk/I-SceI cassette into human q gene intron 2. (C) Vector with 120 nucleotides total homology used to replace the lox511 site
in the BAC vector backbone with a PGK-EM7bsd cassette. The a globin cluster contained in the BAC is shown (not to scale). (D) Vector used to delete
HS -40 within the PROX gene (C16orf35), replacing it with a frt-F3/PGK-EM7puro/frt-F3 cassette. (E) HindIII digests (0.8% gel) of BAC DNAs at each
stage of retrofitting: BAC 344L6 (lane 1), DIST targeted (lane 2), DIST and human q double targeted (lane 3), triple targeted in which BAC vector back-
bone lox511 site is deleted (lane 4), triple targeted with the HS -40 regulatory element deleted (lane 5). (F) Southern blot analysis of HindIII BAC
digested DNA hybridized with probes A–E showing the expected size changes from each progressive modification. Symbols: exons, gray rectangles
(some numbered); noncoding regions and introns, narrow gray rectangles;Hprt-D5
0
segment, red box (pointed end indicating polyadenylation addition
site, blunt end the break in intron sequence); BAC sequences, black lines, or blue lines for the 60 nucleotide (n) homologous sequences. Other sym-
bols as in Figure 2. Restriction enzymes used to generate the homologous ends of the targeting vectors are indicated in (A), (B) and (D); in (C) this was
AscI. Some components not drawn to scale.derived from the 2/B-6 ES cell line and one from the 2/H-1
line were obtained. All three were resistant to ganciclovir,
indicating that Cre-mediated exchange had also occurred
via the lox511 site at the q gene (Figures 4A and 4B). In
addition, the cells were sensitive to hygromycin, puro-
mycin, and G418, indicating that the expected loss of
these markers had occurred (Figure 4B). Sensitivity to
blasticidin suggested that there was no random integra-
tion of the reciprocal BAC product of the exchange event
nor had the BAC DNA integrated by nonhomologous
recombination.
The reconstructed Hprt minigene embedded in the
Dist gene and now flanked by directly repeated frt sites
was subsequently excised by electroporating the FLPe-
expressing plasmid pCAGGS-FLPe-IRESpuro (Schaft
et al., 2001) into the cells. Resistant clones were recovered
at a high frequency after selection in media supplemented
with 6-thioguanine (6-TG). This final modification resulted
in a replacement event in which the only extraneous
sequence remaining is an frt site at the Dist end of theinterval and a lox511site and I-SceI site at the q end
(Figure 4C).
To confirm the anticipated Cre and FLPe recombination
events had occurred at the exchange end points, genomic
DNA from the HATR and 6-TGR clones was analyzed by
extensive Southern blot analysis. Fragments of the pre-
dicted sizes (Figures 4D and 4E [lanes 1 to 6] and Figures
S2 and S3) confirmed that the expected mouse-human
junction sequences had been created at both ends of the
exchange interval. All three of the independent HATR
clones (and their 6-TG-resistant derivative clones) con-
tained the Cre-mediated exchange event.
Generating Mice Containing the Human a Globin
Gene Cluster Replacement
The HATR cell lines with replacements containing the wild-
type human a globin gene cluster (2/B-6R1, 2/B-6R2, and
2/H-1R1, all of which retained the Hprt minigene) were
used to generate chimeras. All three ES cell lines gaveCell 128, 197–209, January 12, 2007 ª2007 Elsevier Inc. 201
Figure 4. Replacement at the Mouse a Globin Locus
(A) Arrangement of sequences in double-targeted ES cells with in-cis chromosomal loxP and lox511 sites and the modified human BAC, also showing
potential Cre-mediated recombination between modified mouse chromosome and BAC. (B) Arrangement of sequences in the recombinant chromo-
some with human replacing mouse sequence and the embedded reconstructed Hprt minigene. (C) Arrangement of sequences in the recombinant
chromosome after removal of the Hprt minigene (D Hprt) by FLPe recombinase. The nontargeted homolog is shown beneath for comparison. (D)
Southern blot analyses following SpeI digestion (0.65% gel) and hybridization with mouse Dist 30 probe (Figure 2). Lane 1, parental ES cells; lane
2, double-targeted cell line 2/B-6; lane 3, double-targeted cell line 2/B-6 HATR exchange clone # 1; lanes 4, 5, and 6, 6-TGR clones derived from
2/B-6 HATR exchange clone # 1; lane 7, 2/B-6 HS -40 deletion HATR exchange clone # 1; lanes 8, 9, and 10, 6-TGR puromycin-sensitive clones derived
from 2/B-6 HS -40 deletion HATR exchange clone # 1. N.B. Lanes 3 and 7 show no alteration in theSpeI fragment size following the exchange because
theHprt gene is still present. (E) Southern blot analyses following aPstI digestion (0.8% gel) and hybridization with mouse 30 q gene 30 probe (Figure 2).
Lanes 1 to 10 as above in (D). Symbols as follows: mouse genes, clear rectangles; mouse intergenic regions, narrow clear rectangles; human genes,
gray rectangles (diagonal division indicates gene overlap); human intergenic regions, narrow gray rectangles; thin black dashed lines with bars,
mouse and human regions delineated by the lox site integrations, size in kilobases (kb); blue dashed lines, predicted Cre recombination between
BAC and chromosome resulting in the exchange. Other symbols as in Figures 2 and 3. Diagram not to scale.rise to male chimeras that transmitted the recombinant
chromosome.
Of the three mouse lines in which the human a globin
regulatory domain replaced the mouse domain, one (line
1, derived from 2/B-6R1) was mapped in detail and a sec-
ond (line 3, derived from 2/H-1R1) in less fine detail. In
both lines, the a globin regulatory domain was shown to
be intact and structurally normal (Figure S2). Line 2 (de-
rived from 2/B-6R2) showed some anomalous bands,
and further investigation (data not shown) demonstrated
this line had an internal deletion of the BAC replacement
region that encompassed at least some of the gene 7
sequence but did not extend into the sequence of the202 Cell 128, 197–209, January 12, 2007 ª2007 Elsevier Inc.MPG or z genes. This deletion was subsequently found
to be present in the ES cell line and presumably arose
during the exchange event. This line was not analyzed
further.
When heterozygotes established on a mixed (129/Ola)/
(C57BL/6)/(CBA) genetic background from both lines (1
and 3) were mated, offspring homozygous for the re-
combinant chromosome were produced but not in the
expected 1 in 4 Mendelian ratio (3 homozygotes: 20 het-
erozygotes: 12 wild-type). Surviving homozygotes devel-
oped normally and were fertile, albeit with significant
hematological abnormalities (see below). From homozy-
gote 3 heterozygote crosses, 6/16 homozygotes were
Table 1. Hematologic Analysis of Humanized Mice
aH/aM mRNA
Hb (g/dl) MCV (Fl) MCH (pg) Retics (%) Real-Time PCR RPA
A
Human BAC line 1 (+H) 15.2 ± 1.0 43.2 ± 2.4 15.6 ± 0.4 1.7 ± 1.1 0.43 ± 0.07 0.39 ± 0.03
Human BAC line 1 (H) 15.0 ± 0.8 45.8 ± 1.1 15.7 ± 0.6 1.9 ± 0.5 0.37 ± 0.07
Human BAC line 3 (+H) 15.5 ± 3.2 44.7 ± 3.1 15.8 ± 1.2 0.8 ± 0.7 0.39 ± 0.04 0.49 ± 0.05
Human BAC line 3 (+H) 14.4 ± 0.7 44.8 ± 1.5 15.3 ± 0.5 1.6 ± 0.6 0.49 ± 0.10
D HS -40 BAC (+H, +P) 13.6 ± 0.4 36.6 ± 1.3 14.4 ± 1.3 2.3 ± 0.5 0.016 ± 0.005 0.016 ± 0.003
D HS -40 BAC (H, P) 14.2 ± 1.5 39.5 ± 3.5 12.9 ± 0.8 2.8 ± 0.7
Normal mouse 15.9 ± 1.1 45.7 ± 2.4 16.5 ± 0.3 1.4 ± 1.0
–/aa 11.8 ± 0.9 36.7 ± 1.5 13.7 ± 0.7 3.9 ± 1.0
B
Human BAC line 1 (+H) 15.2 ± 0.6 39.8 ± 0.8 13.1 ± 0.3 5.8 ± 2.7
Human BAC line 3 (+H) 14.4 ± 0.5 40.0 ± 0.1 13.3 ± 0.2 6.7 ± 1.8
Human BAC line 3 (H) 14.6 ± 2.0 40.0 ± 1.4 13.1 ± 0.3 7.0 ± 4.5
(A) Hematologic data and ratios of human to mouse a globin mRNA levels in adult blood from mice heterozygous for either the intact
human BAC-derived sequence (lines 1 and 3, with theHprt gene present [+H] or after its removal [H] with FLPe recombinase) or one
from which the major regulatory element has been deleted (D HS -40), before (+H, +P) and after removal (H, P) of the Hprt and
puromycin resistance genes. Equivalent results from normal mice and those carrying a deletion of the structural a globin genes are
provided for comparison. n = 3–11 animals. (B) Hematologic data on adult blood from mice (lines 1 and 3) homozygous for the human
BAC-derived sequence, with the Hprt minigene present [+H] or after it was removed [H]. n = 2–5 animals. Hb, level of hemoglobin;
MCV, mean cell volume; MCH, mean cell hemoglobin; Retics, reticulocytes; aH, human a globin; aM, mouse a globin.obtained. Some homozygotes appeared, therefore, to be
lost in utero, and of those that were born, 3/9 died in the
neonatal period.
Mice from lines 1 and 3 were crossed with a FLPe
recombinase germline deleter C57BL/6 strain (unpub-
lished). Analyses of mice carrying the recombinant chro-
mosome and the FLPe transgene confirmed deletion of
the Hprt gene as predicted, and these were subsequently
intercrossed. Southern blot analysis identified embryos
and pups from the intercross that were homozygous for
the now modified recombinant chromosome (Figure S3).
Two viable homozygotes lacking the Hprt gene were pro-
duced and were hematologically indistinguishable from
those that retained the Hprt gene, demonstrating that
the presence of the Hprt gene and its regulatory elements
had no apparent effects on the expression of genes within
the a globin region (Table 1B). After further backcrossing
onto a C57BL/6 background (three generations) heterozy-
gotes with the Hprt gene deleted when intercrossed still
produced a deficiency of viable homozygous offspring.
In Vivo Analysis of Mice Carrying a Human a Globin
Gene Cluster Replacement
To visualize the exchange, splenic lymphocyte meta-
phases from a heterozygote with the recombinant chro-
mosome (line 1) were hybridized with differentially labeled
probes for the mouse and human a globin gene clusters
together with a chromosome 11 paint. In each cell, onechromosome 11 carried a human hybridization signal,
while its homolog bore a mouse signal, confirming that
one of the mouse chromosomes had the human replace-
ment event and that no additional insertions had occurred
(Figure 5).
Expression of the genes from the region containing the
human a globin domain was first checked by hybridization
of RNA from the erythroblasts of a homozygous, human-
ized mouse to an Affymetrix tiled microarray containing
all unique sequences in the terminal 300 kb of chromo-
some 16 (De Gobbi et al., 2006). The pattern of expression
was very similar to that seen from normal human erythro-
blasts (Figure 6A). Using RT-PCR, transcripts from the
MPG, PROX, aD, and aA genes were readily detected in
peripheral blood and spleen (Figure 6B). The low levels
of a globin RNA in brain was consistent with blood con-
tamination. A hybrid RNA crossing the DIST gene break-
point was detected using 50 human and 30 mouse primers
in brain, spleen, and blood from a heterozygote from
which the Hprt minigene had been excised. Similarly, we
detected the hybrid RNA crossing the breakpoint that
lies in the human and mouse q gene (Figure 6C).
Expression of human and mouse a globin mRNA was
measured in adult peripheral blood samples by both quan-
titative real-time PCR and by RNase protection assays
(RPA). The results (Table 1 and Figures 6D–6F) were similar
for both lines analyzed and by both methods and show
that expression from the recombinant chromosome isCell 128, 197–209, January 12, 2007 ª2007 Elsevier Inc. 203
about 40% that of the mouse chromosome. At 9.5 days
gestation, embryos expressed high levels of the embryonic
zglobin gene (zH/(a+ z)H70%, zH/zM60%); the absence
of z gene expression in adults (Figure 6E) confirms that
the normal developmental pattern of globin gene expres-
sion is retained.
Blood films from the mice carrying one copy of the
recombinant chromosome were largely normal in appear-
ance, with a minor increase in anisopoikilocytosis (abnor-
mally shaped cells). No difference was evident between
the two lines. Red cells from the homozygotes were more
markedly abnormal, with microcytic (small), hypochromic
(pale) anisopoikilocytotic cells producing a typical thalas-
semic picture (Figure S4). Blood counts from an automated
counter (ABX Pentra 60) confirmed that in heterozygotes
the Hb level, mean cell volume (MCV), and mean cell hemo-
globin (MCH) were normal, while the homozygotes had
normal Hb levels but a raised reticulocyte count and
reduced MCV and MCH values. These values were similar
(Table 1) to those from thalassemic mice heterozygous for
a targeted deletion (Pa´szty et al., 1995) of both a globin
structural genes (- -/aa).
Deletion of the HS -40 Regulatory Element
in the a Globin Gene Cluster
The RMGR strategy was designed to facilitate rapid re-
cursive introduction of mutations into the exchange
region by additional rounds of BAC modification using l
Red-mediated recombination prior to Cre recombination
in ES cells to allow systematic in vivo functional analyses
of human regulatory elements. As a proof of principle, l
Figure 5. Fluorescence In Situ Hybridization Demonstrating
the Exchange of the Human (Green) andMouse (Red) aGlobin
Regulatory Domains within the Context of Mouse Chromo-
some 11 (Blue)204 Cell 128, 197–209, January 12, 2007 ª2007 Elsevier Inc.Red-mediated recombination was used to remove a 1.1
kb region containing the HS -40 regulatory site that lies
in intron 5 of the C16orf35 (also known as the PROX
gene; gene 7 in Figure 1) gene (Figure 3D) in the triple
targeted BAC. The 1.1 kb region was replaced with a
PGK/EM7puro selection cassette flanked with direct re-
peats of the heterospecific frt site F3 (Schlake and
Bode, 1994); to enable its subsequent excision by FLPe
recombinase without intrachromosomal recombination
occurring with the frt sites flanking the Hprt minigene. Fig-
ures 3D and 3F (lane 5) show the expected change of
a HindIII fragment from 4.1 kb to 4.6 kb. The modified
BAC was coelectroporated into the recipient 2/B-6 ES
cells, in the presence of Cre, and a single HAT-resistant
clone, resistant to ganciclovir and puromycin, was recov-
ered, consistent with the anticipated replacement recom-
bination event. Southern blot analysis of this clone, and of
independent 6-TGR derivative clones (which were also
puromycin sensitive) obtained subsequent to electro-
poration with the FLPe-expressing plasmid, showed the
identical restriction fragment size changes corresponding
to the mouse-human junction sequences (Figures 4D and
4E [lanes 7 to 10]) obtained with the original replacement
event. The frequency of puromycin-sensitive clones (ap-
proximately 50% of total 6-TGR clones) and the identical
restriction fragment size change consistently seen in 6-
TGR puromycin-sensitive clones across the mouse/
human Dist junction indicated that efficient codeletion of
the Hprt and PGK/EM7puro selection cassettes occurred
without heterotypic frt 3 frt-F3 recombination events and
consequent intrachromosomal rearrangement.
Characterization of Mice Carrying a Human a Globin
Gene Cluster Replacement with the HS -40 Deletion
The HATR cell line containing the human a-globin gene
cluster from which HS -40 had been deleted (but retaining
the Hprt minigene) also generated a transmitting male
chimera. Mapping of this line showed only the expected
band sizes.
When these heterozygotes were crossed, homozygotes
were phenotypically indistinguishable from littermates at
10.5 days gestation but by genotyping were detectable
at normal frequencies. By 11.5 days gestation, homozy-
gotes were identifiable as small, pale, dead embryos
that had presumably died from severe anemia.
Expression of the human a globin genes in adult hetero-
zygotes carrying the human cluster from which the major
regulatory element (HS -40) had been deleted (Figure 6E)
was reduced to barely detectable levels (<2%), in keeping
with results from human patients in whom this element is
missing (Higgs et al., 1998). In embryos, human RNA
levels were again severely reduced, with z not as
extremely affected as a (Figure 6F).
Red cell morphology was also abnormal in mice carrying
the mutated human sequence (D HS -40); hypochromia,
microcytosis, and target cells were prevalent as well as
marked anisopoikilocytosis (Figure S4). These films were
similar to those from thalassemic mice heterozygous for
Figure 6. Expression from the Exchanged a Globin Regulatory Domain
(A) hybridization of cDNA from normal human erythroblsts (above) and erythroblasts from a mouse (line 1) homozygous for the replacement event on
a chromosome 16 array (coordinates 1–300,000). (NB: the higher expression of CYXorf1 seen in the human Fibach cells reflects the higher number of
paralogs of this gene [on several chromosomes] in human than in mouse DNA.)
(B) Expression ofMPG,PROX, aD, and a (left panel) was detected in spleen, peripheral blood, and brain samples from a heterozygote from line 1 and in
spleen from a D HS -40 heterozygote, using gene-specific primers. Likewise, expression of Mpg, Prox, and a was present in the murine locus (right
panel). Low levels of expression of a globin in nonerythroid tissues is due to contamination with small amounts of blood.
(C) RT-PCR analysis of mRNA expression across the murine/human junction (Dist and q genes) in spleen, peripheral blood and brain samples from
a heterozygote line 1 or D HS -40 mouse in which the Hprt gene has been excised from the Dist gene. A correct size transcript is observed across the
junction (arrows), showing that the gene expression is not affected. Note that in the absence of the HS -40 element, q gene expression is severely
downregulated.
(D) RNase protection assays of 10.5 day heterozygous embryos showing expression of mouse and human z and a genes.
(E) RNase protection assay of adult blood RNA from heterozygotes of lines 1 and 3 and the D HS -40 line.
(F) RNase protection assays of embryonic blood (9.5 days) from heterozygotes and homozygotes for the recombinant chromosome from which the
HS -40 element was deleted.Cell 128, 197–209, January 12, 2007 ª2007 Elsevier Inc. 205
a targeted deletion (Pa´szty et al., 1995) of both a globin
structural genes (- -/aa). Blood counts showed a reduced
Hb level and low MCV and MCH, similar to those from --/aa
mice (Table 1). The puromycin selection marker gene,
which replaced the HS -40 element, and theHprtminigene
were excised by crossing this line with the FLPe recombi-
nase deleter line. Hematological analyses of two adult
mice derived from this cross carrying the now modified,
mutated human sequence were indistinguishable from
mice in which these selection marker genes had not been
excised (Table 1).
DISCUSSION
Here we have shown that it is possible to precisely replace
a large segment of the mouse genome containing multiple
loci with the corresponding, syntenic segment of the
human genome. Combining a variety of developments in
chromosome engineering, RMGR has significantly ex-
tended the principles underpinning RMCE to enable
extensive tracts (100s to 1000s kb) of mouse genomic
DNA to be replaced by the orthologous sequences of
other species cloned in BAC libraries. RMGR will therefore
be widely applicable and offers several advantages over
other approaches to large-scale genome modification. In
particular, correct genomic replacement using RMGR is
genetically selectable, precise, and reproducible. This re-
duces the effort of screening and greatly simplifies the
characterization of the chromosomal breakpoints. Mini-
mal extraneous DNA remains to affect the functional integ-
rity of the engineered chromosomal region, provided the
locations of the recombination sites are chosen carefully.
Once correctly targeted, germline transmitting ES cells are
established, RMGR allows iterative replacement with mu-
tated BACs for detailed functional dissection of genomic
sequences. Although the frequency of replacement is
low, it is reproducible. General application may reveal lo-
cus-specific and/or BAC-specific variations in efficiency
requiring adjustments to the electroporation parameters.
The RMGR strategy will be adaptable for application
with other (e.g., fC31) (Belteki et al., 2003) site-specific re-
combination systems to improve the overall efficiency and
allow the Cre/lox system to be used to introduce condi-
tional deletions within the human sequence. In its present
form, the extent of sequence replacement is limited only
by the size of the BAC inserts. Recent approaches to
construct mega-BACs (Shen et al., 2005) in E. coli will
therefore extend the size range of replacements possible.
By analyzing the well-characterized a globin regulatory
domain by RMGR, we could be confident that the structur-
ally intact segment contains all known cis-acting ele-
ments, at a single copy in a chromosomal position that
is appropriate for globin gene expression. Furthermore,
by carefully examining gene expression in erythropoiesis
and evaluating the resulting, sensitive red cell phenotype,
we could accurately assess the degree to which regulation
of the human globin genes mimic their normal pattern and
levels of expression in the mouse model. We found that206 Cell 128, 197–209, January 12, 2007 ª2007 Elsevier Inc.under these conditions the human genes are expressed
in an appropriate developmental stage- and tissue-spe-
cific manner, although the level of expression of the
a genes is only about 40% of that of the endogenous
mouse a globin genes. This leads to abnormal red blood
cells, and homozygotes for the human synteny replace-
ment may die prematurely even though they are not
frankly anemic. These differences between expression
of the human gene in man and mouse could result from
changes in the chromosomal environment, although the
relationship between transcription and nuclear sublocali-
zation remains unclear (Brown et al., 2006). Perhaps
more likely, changes in the structure or recognition se-
quences of the key transcription factors have altered
during the evolution of the two species such that the bind-
ing or stability of mouse transcription factors on human
sequences are suboptimal.
Knowing the phenotype resulting from expression of the
normal human a globin cluster in mouse, it is now possible
to compare and evaluate the effects of specific mutations
introduced into the human sequence. Using RMGR, the
only variable is the mutation itself. Such mutations could
either be introduced by further rounds of homologous
recombination in the humanized ES cells or, as demon-
strated here, by recombineering the appropriate mutation
into the modified BAC followed by a new round of RMGR
at the target region. Again using the a globin cluster as the
model we could show that removal of just 1.1 kb contain-
ing the major regulatory element (HS -40) virtually abol-
ishes human a globin expression consistent with previous
extensive observations (Higgs et al., 1998). In homozy-
gotes, this deletion mimics the lethal clinical phenotype
of hydrops fetalis seen in human patients with this degree
of a globin deficiency. We have previously shown that
removal of the mouse sequence (HS -26), which is the
equivalent of the human major regulatory element (HS -40),
from the endogenous locus only reduces mouse a globin
expression to 50% of normal, and homozygotes for
this allele survive with only mild anemia rather than devel-
oping hydrops fetalis (Anguita et al., 2002). This clearly
shows that the detailed regulation of human and mouse
genes may be quite different and emphasizes the point
that extrapolating conclusions from studying regulation
of an orthologous gene may be misleading when one
wishes to determine how a particular human gene is
regulated.
It seems likely that the observations set out here repre-
sent general recurrent issues that arise when making and
analyzing mouse models of human gene regulation and
genetic disease. RMGR will exclude most of the variables
associated with current transgenic experiments, but it is
still likely that human genes will not be completely faithfully
regulated in mouse systems. However, comparing wild-
type and mutant chromosomal domains iteratively in-
serted into an appropriate chromosomal environment
will allow one to determine more precisely the effect of
specific mutations. This will not only be of value when
studying previously well-characterized loci but will also
enable those studying complex traits to assess the func-
tional role of mutations and SNPs localized within less
well characterized large segments of the human genome.
EXPERIMENTAL PROCEDURES
ES Cell Gene Targeting Vectors
Replacement vectors were constructed in pBluescript (pBS) plasmid
using 129/Ola strain cloned genomic DNA; (see Supplemental Data
Section S1 for details). Vectors were linearized at a unique restriction
site prior to electroporation.
BAC Retrofitting Vectors
Vectors were constructed in pBS plasmid using subcloned human
BAC 344L6 DNA or duplex synthetic oligonucleotides, and selection
cassettes with dual eukaryotic (PGK) and prokaryotic (Tn903 or EM7)
promoters (Testa et al., 2003); (see Supplemental Data Section S2
for details). DNA restriction fragments used for electroporation were
gel purified from the pBS backbone.
BAC Modifications
The BAC 344L6 was transferred into E. coli DY380 (gift from D. Court
and N. Copeland) selected in chloramphenicol 12.5 mg/ml and electro-
competent cells then prepared for retrofitting (Lee et al., 2001). l Red-
mediated recombination was carried out mixing 50 ml of cells with 150
ng to 300 ng purified DNA in a 0.1 cm wide cuvette using a Bio-Rad
gene pulser set at 1.8 kV. Immediately after electroporation, 1 ml of
SOC media was added, and the cells were further grown at 32C for
2 hr before being plated on appropriate selective agar media. Drug
concentrations: puromycin, 62.5 mg/ml; kanamycin, 12.5 mg/ml; blasti-
cydin, 100 mg/ml; hygromycin, 50 mg/ml.
ES Cell Gene Targeting
E14-TG2a.IV ES cells were grown as previously described (Nichols
et al., 1990). 75 mg of NotI linearized Dist targeting vector was electro-
porated into 53 107 E14-TG2a.IV cells as previously described (Smith
et al., 2002). Cells were selected in 160 mg/ml G418 and resistant
colonies later picked into 96-well plates for freezing and DNA analysis.
Targeted clones were identified by Southern blot analysis of SpeI
digested DNAs and hybridization with 50 and 30 external probes (50,
0.96 kb BamHI - HindIII fragment; 30, 0.90 kb SpeI - BglII fragment).
The Dist-targeted cell line was then used in a second round of electro-
poration to target the 30 q gene according to the procedure above.
Cells were selected in 1.5 mg/ml puromycin. Targeted clones were
identified by Southern blot analysis of PstI-digested DNAs and hybrid-
ization with 50 and 30 external probes (50, 0.22 kb XhoI/HindIII fragment;
30, 0.45 kb BglII fragment).
Determination of in-cis Double Targeted Clones
Double-targeted ES cell clones were coelectroporated with 75 mg pBS
vector containing a loxP/Hprt-D5
0
/lox511 cassette and 25 mg pCAGGS-
Cre-IRESpuro plasmid (Smith et al., 2002). 24 hr later, cells were plated
at 53 106 cells per 10 cm dish. Cells were selected the following day in
HAT supplemented medium (0.1 mM hypoxathine, 0.4 mM aminopterin,
0.016 mM thymidine). After 10 days, HATR colonies were counted,
picked into 96-well plates, and subsequently replica 96-well plates
made for G418 and puromycin resistance/sensitivity testing. Details
are provided in Supplemental Data Section S3.
BAC Exchange
Approximately 80 mg of retrofitted supercoiled BAC DNA (see Supple-
mental Data Section S4 for DNA preparation method) and 30 mg
pCAGGS-Cre-IRESpuro plasmid DNA (1:10 molar ratio) were mixed
and coprecipitated with ethanol. The DNA pellet was dissolved in a final
volume of 100 ml 90% phosphate-buffered saline (PBS), and the DNAs
were very gently mixed with a 0.7 ml suspension of 53 107 to 13 108double-targeted ES cells in PBS in a 0.4 cm wide Bio-Rad cuvette.
Cells were electroporated at 0.25 kV, 960 mF using a Bio-Rad gene
pulser and then plated into twenty 10 cm diameter dishes. 24 hr later,
HAT supplemented media was added and left for 4 days. The medium
was then changed to HT (0.1 mM hypoxanthine plus 0.016 mM thymi-
dine) supplemented media, and any resistant colonies were picked
6–10 days later. The clones were subsequently expanded for freezing,
DNA analysis, and testing resistance/sensitivity to the following: G418
(160 mg/ml), hygromycin (120 mg/ml), puromycin (1.5 mg/ml), blasticy-
din (5 mg/ml), ganciclovir (2.5 mM), 6-thioguanine (10 mM), HAT
(0.1 mM hypoxathine, 0.4 mM aminopterin, 0.016 mM thymidine).
DNA of potential replacement clones was first analyzed at the end
points of the exchange event by SpeI digestion and hybridization
with 50 and 30 mouse Dist probes and PstI digestion and hybridization
with 50 and 30 mouse 30 q probes.
Hprt Cassette Deletion
Clones with a confirmed exchange event were electroporated with
75 mg supercoiled pCAGGS-FLPe-IRESpuro plasmid DNA (Schaft
et al., 2001). The cells were grown nonselectively for 6 days and then
plated out at 103 cells per 10 cm plate in medium with 10 mM 6-thiogua-
nine. Resistant colonies were picked after 8 days into a 96-well plate
for freezing and DNA analysis.
Generation of Chimeras and Breeding
All animal experiments were conducted under Home Office licenses
after ethical review of the Universities of Edinburgh and Oxford. Chi-
meras were generated by injection of ES cells into C57/BL6 blasto-
cysts and transfer into pseudopregnant recipients. Male chimeras
were test-crossed with C57/BL6 mice. Agouti F1 test-cross offspring
were genotyped byEcoRI digestion of tail biopsied DNA and hybridiza-
tion with a human z gene probe. Test-cross positive heterozygotes
were further backcrossed onto the C57BL/6 strain to maintain the
lines. Test-cross positive heterozygotes were also bred with C57BL/
6 3 CBA F1 mice, and heterozygotes on this mixed genetic back-
ground intercrossed to derive homozygotes. To derive lines with the
Hprt cassette removed, F1 test-cross positive heterozygotes were
crossed with a C57BL/6 FLPe germline deleter, and these were subse-
quently maintained by backcrossing with C57BL/6 mice and heterozy-
gotes intercrossed to derive homozygotes.
DNA and RNA Analysis
Genomic DNA analysis and RNase protection assays were as previ-
ously described (Anguita et al., 2002). DNA FISH studies were as
described (Brown et al., 2006).
Total RNA was isolated from adult tissues or whole embryos using
the Trizol reagent (Sigma) and analyzed by Affymetrix array as previ-
ously described (De Gobbi et al., 2006) and by quantitative real-time
RT-PCR. Specific primers and TaqMan probes were designed with
Primer Express software (ABI) and sequences used are provided in
Table S2.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.cell.com/cgi/content/full/128/1/197/DC1/.
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